Loading…
WELL PHARMACEUTICALS COLD AND FLU RELIEF is a brand name for Phenylephrine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For relief of the symptoms of colds and influenza, including the relief of aches and pains, sore throat, headache, nasal congestion and lowering of temperature.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults, the elderly and children aged 16 years and above: :
One sachet dissolved by stirring in hot water, but not boiling water and sweetened to taste. Not more than four sachets to be taken in 24 hours. The dose may be repeated in 4-6 hours.
Children under 16 years:
Not recommended for children under 16 years of age. Method of administration Oral administration after dissolution in water.
Paracetamol The frequency using the following convention: very common (> 1/10); common (>1/100 to < 1/10); uncommon (>1/1000 to < 1/100); rare (>1/10000 to < 1/1000); very rare (< 1/10000), including isolated reports; not known: frequency cannot be estimated from the available data.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. System Organ Class Frequency Symptoms Rare Platelet disorders, stem cell disorders. Very Rare Thrombocytopenia, leukopenia, neutropenia, hemolytic anaemia agranulocytosis1 Blood and lymphatic system disorders Not Known pancytopenia Immune system disorders Rare Hypersensitivity (excluding angioedema).
Very Rare HypoglycaemiaMetabolism and nutrition disorders Not known High anion gap metabolic acidosis3 Psychiatric disorders Rare Depression NOS, confusion, hallucinations. Nervous system disorders Very Rare Tremor NOS, headache NOS Eye disorders Rare Abnormal vision.
Cardiac disorders Rare Oedema. Gastrointestinal disorders Rare Haemorrhage NOS, abdominal pain NOS, diarrhoea NOS, nausea, vomiting. Hepato-biliary disorders Rare Hepatic function abnormal, hepatic failure, hepatic necrosis, jaundice.
Very Rare Hepatotoxicity Rare Pruritus, rash, sweating, purpura, angioedema, urticaria. Very rare Cases of serious skin reactions have been reported. Skin and subcutaneous tissue disorders Not Known Skin rash Very Rare Sterile pyuria (cloudy urine) and renal side effects Renal and urinary disorders Not Known Urinary retention2 Rare Dizziness (excluding vertigo), malaise, pyrexia, sedation, drug interaction NOS.
General disorders and administration site conditions Very Rare hypersensitivity reaction (requiring discontinuation of treatment) Injury, poisoning and procedural complications Very Rare Overdose and poisoning Not known: Some cases of edema of the larynx, anaphylactic shock, anaemia, bronchospasm*, liver alteration and hepatitis, renal alteration (severe renal impairment, nephrite interstitial, haematuria, anuresis), gastrointestinal effects and vertigo have been reported.
Paracetamol Prolonged or frequent use is discouraged. Patients should be advised not to take other Paracetamol containing products concurrently. Taking multiple daily doses in one administration can severely damage the liver; in such case unconsciousness does not occur.
However, medical assistance should be sought immediately. Prolonged use except under medical supervision may be harmful. In adolescents treated with 60mg/kg daily of Paracetamol, the combination with another antipyretic is not justified except in the case of ineffectiveness.
2). g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended.
The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors. The hazards of overdose are greater in those with non- cirrhotic alcoholic liver disease.
Caution should be exercised in cases of chronic alcoholism. The daily dose should not exceed 2 grams in such case. Alcohol should not be used during the treatment with Paracetamol. Caution is advised in asthmatic patients sensitive to aspirin, because light reaction bronchospasm with paracetamol (cross-reaction) has been reported in less than 5% of the patients tested.
Phenylephrine Phenylephrine should be used with care in patients with cardiovascular disease, diabetes mellitus, closed angle glaucoma, prostatic enlargement and hypertension. Phenylephrine hydrochloride may increase blood pressure and therefore special care is advisable in individuals receiving antihypertensive treatment.
Caution should also be exercised by individuals taking beta-adrenergic blocking agents. Use with caution in occlusive vascular disease (Raynaud’s syndrome) or diabetes mellitus.
5). • Beta-blockers
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Phenylephrine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
* There have been cases of bronchospasm with paracetamol, but these are more likely in asthmatics sensitive to aspirin or other NSAIDs. Description of Selected Adverse Reactions 1 There have been reports of blood dyscrasias including thrombocytopenia, leucopenia, pancytopenia, neutropenia and agranulocytosis, but these were not necessarily causally related to paracetamol.
4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients. Phenylephrine The following adverse events have been observed in clinical trials with phenylephrine and may therefore represent the most commonly occurring adverse events.
Body System Undesirable effect Psychiatric disorders Nervousness, irritability, restlessness, and excitability Nervous system disorders Headache, dizziness, insomnia Cardiac disorders Increased blood pressure Gastrointestinal disorders Nausea, Vomiting.
Vascular disorders Hypertension Adverse reactions identified during post-marketing use are listed below. The frequency of these reactions is unknown but likely to be rare. g. rash, urticaria, allergic dermatitis). Hypersensitivity reactions – including that cross-sensitivity may occur with other sympathomimetics Renal and urinary disorders Dysuria, urinary retention.
This is most likely to occur in those with bladder outlet obstruction, such as prostatic hypertrophy. Reporting of Suspected Adverse Reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card on the Google Play or Apple App Store.
Important information regarding the ingredients of this medicine Aspartame:
This medicinal product contains aspartame, which is a source of phenylalanine. May be harmful for people with phenylketonuria.
Sucrose:
This medicinal product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase- isomaltase insufficiency should not take this medicine. 81 % of the WHO recommended maximum daily intake for sodium.
This medicinal product is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
+3 more